hn.today

Car T-cell therapy shows promise in patients with multiple myeloma

news.massgeneralbrigham.org4 points0 comments
Screenshot of Car T-cell therapy shows promise in patients with multiple myeloma

TriPRIL is an experimental CAR T-cell therapy designed for multiple myeloma that has returned or resisted treatment. Unlike existing CAR T-cell therapies that target only BCMA, TriPRIL uses a human-protein-based receptor to recognize both BCMA and TACI on cancer cells. The second target may help the modified immune cells attack myeloma even when cells stop displaying BCMA, a change that can contribute to relapse. Researchers also expect the human-derived design may reduce immune reactions against the therapy.

In a first-in-human phase 1 trial at Mass General Brigham, 15 heavily treated patients received TriPRIL; nine had previously received BCMA-targeted CAR T-cell therapy. Twelve patients (80%) had a reduction of at least half in signs of cancer, and eight (53%) had no active myeloma detected in blood, urine, or bone marrow tests. TriPRIL cells remained detectable in some patients for more than six months. No severe cases of cytokine release syndrome or neurotoxicity occurred, and tested patients showed no immune reaction to TriPRIL. These early results are encouraging, particularly for patients whose disease progressed after BCMA-directed treatment, but the small trial and short follow-up cannot establish how durable the benefits are or reveal uncommon side effects. A larger phase 2 study is planned.

Read on news.massgeneralbrigham.org0 comments on Hacker News

Summary generated by AI from the linked article. hn.today is not affiliated with Hacker News or Y Combinator.

More in Science

Lindy Effect

Lindy Effect

The Lindy effect proposes that non-perishable ideas and technologies gain longer expected future lifespans the longer they have already endured. Named after a New York deli, the idea is associated with a Pareto distribution and does not apply to things with fixed expiration dates, such as human lives. (en.wikipedia.org)

The daily digest

Today's best Hacker News stories, summarized and screenshotted, one email a day.